Market Closed -
Nyse
04:00:02 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
229.6
USD
|
+1.11%
|
|
-0.68%
|
-0.77%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
29,981
|
34,352
|
53,900
|
38,056
|
42,227
|
41,833
|
-
|
-
|
Enterprise Value (EV)
1 |
40,789
|
44,983
|
64,659
|
49,587
|
54,524
|
53,768
|
53,538
|
52,723
|
P/E ratio
|
161
x
|
125
x
|
57
x
|
35.8
x
|
31.7
x
|
31.3
x
|
26.3
x
|
22.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.7
x
|
3.02
x
|
3.88
x
|
2.64
x
|
2.82
x
|
2.7
x
|
2.53
x
|
2.37
x
|
EV / Revenue
|
3.68
x
|
3.96
x
|
4.66
x
|
3.44
x
|
3.64
x
|
3.47
x
|
3.23
x
|
2.99
x
|
EV / EBITDA
|
17
x
|
18.9
x
|
21.4
x
|
14.8
x
|
15.3
x
|
14.4
x
|
13.2
x
|
12.1
x
|
EV / FCF
|
48.8
x
|
33.5
x
|
28.1
x
|
31.3
x
|
36.3
x
|
30.4
x
|
24.8
x
|
21.3
x
|
FCF Yield
|
2.05%
|
2.99%
|
3.56%
|
3.2%
|
2.75%
|
3.29%
|
4.03%
|
4.69%
|
Price to Book
|
4.95
x
|
5.71
x
|
9.11
x
|
6.6
x
|
7.05
x
|
6.27
x
|
5.72
x
|
4.99
x
|
Nbr of stocks (in thousands)
|
194,038
|
191,726
|
191,040
|
185,740
|
182,500
|
182,200
|
-
|
-
|
Reference price
2 |
154.5
|
179.2
|
282.1
|
204.9
|
231.4
|
229.6
|
229.6
|
229.6
|
Announcement Date
|
2/12/20
|
2/10/21
|
2/15/22
|
2/10/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11,088
|
11,359
|
13,874
|
14,410
|
14,984
|
15,482
|
16,562
|
17,660
|
EBITDA
1 |
2,400
|
2,384
|
3,022
|
3,346
|
3,569
|
3,738
|
4,052
|
4,357
|
EBIT
1 |
2,112
|
2,030
|
2,591
|
2,779
|
3,050
|
3,157
|
3,434
|
3,736
|
Operating Margin
|
19.05%
|
17.87%
|
18.68%
|
19.29%
|
20.36%
|
20.39%
|
20.73%
|
21.15%
|
Earnings before Tax (EBT)
1 |
352
|
373
|
1,128
|
1,363
|
1,459
|
1,638
|
1,969
|
2,305
|
Net income
1 |
191
|
279
|
966
|
1,091
|
1,358
|
1,336
|
1,576
|
1,821
|
Net margin
|
1.72%
|
2.46%
|
6.96%
|
7.57%
|
9.06%
|
8.63%
|
9.51%
|
10.31%
|
EPS
2 |
0.9600
|
1.430
|
4.950
|
5.720
|
7.290
|
7.334
|
8.733
|
10.23
|
Free Cash Flow
1 |
835
|
1,343
|
2,302
|
1,586
|
1,500
|
1,769
|
2,156
|
2,472
|
FCF margin
|
7.53%
|
11.82%
|
16.59%
|
11.01%
|
10.01%
|
11.43%
|
13.02%
|
14%
|
FCF Conversion (EBITDA)
|
34.79%
|
56.33%
|
76.17%
|
47.4%
|
42.03%
|
47.34%
|
53.21%
|
56.75%
|
FCF Conversion (Net income)
|
437.17%
|
481.36%
|
238.3%
|
145.37%
|
110.46%
|
132.39%
|
136.85%
|
135.74%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/12/20
|
2/10/21
|
2/15/22
|
2/10/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3,636
|
3,568
|
3,541
|
3,562
|
3,739
|
3,652
|
3,728
|
3,736
|
3,868
|
3,737
|
3,793
|
3,876
|
4,068
|
4,000
|
4,098
|
EBITDA
1 |
828
|
812
|
800
|
814
|
920
|
851
|
864
|
888
|
966
|
862
|
885
|
955.8
|
1,041
|
929.4
|
975.4
|
EBIT
1 |
704
|
691
|
682
|
694
|
712
|
721
|
737
|
747
|
821
|
738
|
750.2
|
800.1
|
881.3
|
789.1
|
821.8
|
Operating Margin
|
19.36%
|
19.37%
|
19.26%
|
19.48%
|
19.04%
|
19.74%
|
19.77%
|
19.99%
|
21.23%
|
19.75%
|
19.78%
|
20.64%
|
21.67%
|
19.73%
|
20.05%
|
Earnings before Tax (EBT)
1 |
376
|
400
|
328
|
360
|
275
|
362
|
375
|
349
|
373
|
340
|
371.8
|
426
|
504.2
|
414.3
|
452.7
|
Net income
1 |
318
|
325
|
256
|
283
|
227
|
289
|
297
|
303
|
469
|
288
|
304.5
|
344.5
|
409.8
|
330.9
|
362.2
|
Net margin
|
8.75%
|
9.11%
|
7.23%
|
7.94%
|
6.07%
|
7.91%
|
7.97%
|
8.11%
|
12.13%
|
7.71%
|
8.03%
|
8.89%
|
10.08%
|
8.27%
|
8.84%
|
EPS
2 |
1.630
|
1.680
|
1.340
|
1.490
|
1.200
|
1.530
|
1.590
|
1.630
|
2.540
|
1.560
|
1.623
|
1.847
|
2.188
|
1.830
|
2.012
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/15/22
|
4/27/22
|
7/21/22
|
10/26/22
|
2/10/23
|
4/27/23
|
8/1/23
|
11/1/23
|
2/14/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
10,808
|
10,631
|
10,759
|
11,531
|
12,297
|
11,935
|
11,705
|
10,890
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
4.503
x
|
4.459
x
|
3.56
x
|
3.446
x
|
3.446
x
|
3.193
x
|
2.888
x
|
2.5
x
|
Free Cash Flow
1 |
835
|
1,343
|
2,302
|
1,586
|
1,500
|
1,769
|
2,156
|
2,472
|
ROE (net income / shareholders' equity)
|
20.1%
|
20.9%
|
29.2%
|
32.8%
|
32%
|
31.7%
|
32.9%
|
33.6%
|
ROA (Net income/ Total Assets)
|
5.57%
|
1.17%
|
7.15%
|
7.74%
|
5.22%
|
6.36%
|
7.03%
|
7.96%
|
Assets
1 |
3,428
|
23,907
|
13,517
|
14,088
|
26,009
|
21,028
|
22,425
|
22,867
|
Book Value Per Share
2 |
31.20
|
31.40
|
31.00
|
31.00
|
32.80
|
36.60
|
40.20
|
46.00
|
Cash Flow per Share
2 |
7.100
|
10.00
|
15.10
|
11.90
|
11.50
|
14.50
|
16.90
|
19.00
|
Capex
1 |
582
|
616
|
640
|
674
|
649
|
638
|
670
|
731
|
Capex / Sales
|
5.25%
|
5.42%
|
4.61%
|
4.68%
|
4.33%
|
4.12%
|
4.04%
|
4.14%
|
Announcement Date
|
2/12/20
|
2/10/21
|
2/15/22
|
2/10/23
|
2/14/24
|
-
|
-
|
-
|
Last Close Price
229.6
USD Average target price
271.4
USD Spread / Average Target +18.22% Consensus |
1st Jan change
|
Capi.
|
---|
| -0.77% | 41.83B | | +67.53% | 63.85B | | +45.66% | 40.65B | | -10.72% | 27.12B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B | | -8.12% | 11.19B |
Other Biotechnology & Medical Research
|